Skip to content

Arbutus Biopharma Corp

ABUS· NasdaqCore metricsCIK 1447028

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · +3.73%
Market cap
$617.77M
153.29M shares
Filings
1,029
$299.00K
Q3 2026+128.2% FY25 yoy
$59.12M
Q3 2026N/M FY25 yoy
-$10.49M
Q3 2026N/M FY25 yoy
-$39.64M
FY 2025derivedN/M FY25 yoy
$0.30
Q3 2026N/M FY25 yoy
$264.19M
Q3 2026−50.4% FY25 yoy
$617.77M
2.8×
3.4×
7.2×
—
—

Twelve months to Sep 30, 2026 · derived

Price

$4.0314.44%$0.68past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$14.08MFY 2025
$39.02M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$14,083,000reported
FY 20242024-12-31$6,171,000reported
FY 20232023-12-31$18,141,000reported
FY 20222022-12-31$39,019,000reported
FY 20212021-12-31$10,988,000reported
FY 20202020-12-31$6,914,000reported
FY 20192019-12-31$6,011,000reported
FY 20182018-12-31$5,945,000reported
FY 20172017-12-31$10,700,000reported
FY 20162016-12-31$1,491,000reported
FY 20152015-12-31$23,276,000 revisedreported
FY 20142014-12-31$14,953,000reported

Segments

Products
Revenue by Products, FY2019 to FY2025FY2019Collaborations and licenses · FY2019 · $4.36MNon-cash royalty revenue · FY2019 · $1.66MFY2020Collaborations and licenses · FY2020 · $3.52MNon-cash royalty revenue · FY2020 · $3.40MFY2021Collaborations and licenses · FY2021 · $4.88MNon-cash royalty revenue · FY2021 · $6.11MFY2022Collaborations and licenses · FY2022 · $31.37MNon-cash royalty revenue · FY2022 · $7.65MFY2023Collaborations and licenses · FY2023 · $14.27MNon-cash royalty revenue · FY2023 · $3.87MFY2024Collaborations and licenses · FY2024 · $3.92MNon-cash royalty revenue · FY2024 · $2.25MFY2025Collaborations and licenses · FY2025 · $12.60MNon-cash royalty revenue · FY2025 · $1.48M
LineFY2025ShareChange
Collaborations and licenses$12.60M89%+221.5%
Non-cash royalty revenue$1.48M11%−34.2%
Total$14.08M

From the 10-K filed Mar 23, 2026ABUS

Pharmaceutical preparations

Arbutus Biopharma Corp is the 159th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Arbutus Biopharma Corp · CIK 1447028 · Engraved from SEC EDGAR